NZ firm Virionyx hits rich research vein
04 August, 2003 by Jeremy TorrNew Zealand biotech Virionyx has hit a rich vein with a development deal for a frontline therapy suitable for a range of high-level infections such as AIDS, SARS, West Nile virus and dengue fever -- plus bioterrorism threats.
Chemeq announces $7m loss
28 July, 2003 by Jeremy TorrWA antimicrobial vet biotech Chemeq (ASX: CMQ) has listed a AUD$7.2 million loss for the 2002-03 fiscal year, described as "in line with the company's budget" despite a recent $25 million injection from share placements.
Fundraising activity nets $8m for Stem Cell Sciences
25 July, 2003 by Melissa TrudingerMelbourne company Stem Cell Sciences has emerged from recent capital-raising activities AUD$8 million better off.
NSCC looks towards global stage
23 July, 2003 by Melissa TrudingerProf Alan Trounson is stepping away from his role as CEO of the National Stem Cell Centre (NSCC) to become its Global Science Strategic Advisor, with a focus on expanding the centre's international relationships and influence.
'Artistic' rat cells could shed light on learning
11 July, 2003 by Jeremy TorrAustralian and US researchers have combined efforts to produce artistic rat cells, which can paint pictures across the world from their Petri dish. And hopefully give some insight into the learning process at the same time.
Germline therapy tipped for longer life
09 July, 2003 by Graeme O'NeillEvolution doesn't care what happens to the body after reproduction, says Prof Miroslav Radman, so we humans should consider taking out little extra cellular life insurance to ward off cancer in our twilight years.
New study points to possible 'flu firewall'
27 May, 2003 by Graeme O'NeillAn Australian-US study has shown it may be possible to develop a 'firewall' vaccine against the world's most dangerous human pathogen, the influenza virus.
Qld firm 'days away' from SARS test
21 May, 2003 by Jeremy TorrA Queensland biotech recently involved in a TV-driven stoush with defence scientists over anthrax-detecting equipment says it is days away from a working, non-invasive SARS test.
Stem cell summit planned for NSW
21 May, 2003 by Iain ScottA Sydney workshop to showcase the latest research involving stem cells has been set down for June 4.
Stem cells are today's gene therapy: Colman
19 May, 2003 by Jeremy TorrSpeaking to a packed room of delegates at the Discovery Science and Biotechnology conference in Sydney last week, cloning pioneer Alan Colman described stem cell research as being in the same boat as gene therapy a decade ago.
Agenix appoints board, aims to strengthen blood business
13 May, 2003 by Pete YoungListed biotech Agenix is ringing in changes to bolster its current blood diagnostics business while promoting the progress of its intended next-generation product, the Thromboview blood clot-imaging agent.
Aust stem cell laws 'enlightened': US bioethicist
09 April, 2003 by Melissa TrudingerA leading US bioethicist has praised Australia's new stem cell laws, describing them as enlightened.
Singapore cord blood firm to set up in Australia
08 April, 2003 by Jeremy TorrSingapore-based CordLife is looking to establish a local cord blood facility for as a precursor to expanding Australian operations in stem cell (haematopoietic stem cells or HSC) research.
Norwood Abbey spins out immunology project
03 April, 2003 by Melissa TrudingerNorwood Abbey has spun out its immunology project into a separate company, which will be listed in Europe or the USA within the next 12 months.
Oncomab, Medarex to develop antibodies
19 March, 2003 by Melissa TrudingerPrima BioMed (ASX:PRR) subsidiary Oncomab has entered into a joint venture with US humanised antibody company Medarex to co-develop and commercialise fully human antibodies for the treatment of cancer.
